SABS SAB BIOTHERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, SAB BIOTHERAPEUTICS INC reported revenue of n/a, net income of −$22.5M and diluted EPS of −$0.28; for the fiscal year ended December 2025 revenue was $0, down 100.0% on the year before.

SABS annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $0, gross profit n/a, operating income −$49.0M, net income $13.3M (margin n/a), EPS −$0.79
• Fiscal year ended Dec 2024: revenue $1.32M, gross profit n/a, operating income −$42.9M, net income −$34.1M (margin -2579.0%), EPS −$3.68
• Fiscal year ended Dec 2023: revenue $2.24M, gross profit n/a, operating income −$38.1M, net income −$42.2M (margin -1884.5%), EPS −$7.64
• Fiscal year ended Dec 2022: revenue $23.9M, gross profit n/a, operating income −$28.9M, net income −$18.7M (margin -78.4%), EPS −$4.31
• Fiscal year ended Dec 2021: revenue $60.9M, gross profit n/a, operating income −$13.4M, net income −$17.1M (margin -28.2%), EPS −$0.63

SABS quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue n/a, net income −$22.5M, EPS −$0.28
• Quarter ended Mar 31, 2026: revenue n/a, net income −$18.9M, EPS −$0.35
• Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$16.9M, EPS $1.07
• Quarter ended Sep 30, 2025: revenue n/a, net income $45.4M, EPS −$0.21
• Quarter ended Jun 30, 2025: revenue n/a, net income −$10.1M, EPS −$1.09
• Quarter ended Mar 31, 2025: revenue n/a, net income −$5.20M, EPS −$0.56
• Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$11.4M, EPS −$1.23
• Quarter ended Sep 30, 2024: revenue n/a, net income −$10.3M, EPS −$1.12
• Quarter ended Jun 30, 2024: revenue $263K (up 207.7% year over year), net income −$7.34M, EPS −$0.79
• Quarter ended Mar 31, 2024: revenue $945K (up 62.5% year over year), net income −$5.03M, EPS −$0.54
• Quarter ended Dec 31, 2023 (from the annual report): revenue $305K (down 85.9% year over year), net income −$22.9M, EPS −$3.85
• Quarter ended Sep 30, 2023: revenue $1.27M (down 64.7% year over year), net income −$5.10M, EPS −$0.97
• Quarter ended Jun 30, 2023: revenue $85.5K (down 98.7% year over year), net income −$6.88M, EPS −$1.36
• Quarter ended Mar 31, 2023: revenue $581K (down 95.1% year over year), net income −$7.35M, EPS −$1.46
• Quarter ended Dec 31, 2022 (from the annual report): revenue $2.16M (down 80.5% year over year), net income −$7.87M, EPS −$4.06
• Quarter ended Sep 30, 2022: revenue $3.59M (down 75.5% year over year), net income −$7.08M, EPS −$0.16
• Quarter ended Jun 30, 2022: revenue $6.35M (down 65.1% year over year), net income −$4.78M, EPS −$0.11
• Quarter ended Mar 31, 2022: revenue $11.8M (down 30.3% year over year), net income $986K, EPS $0.02
• Quarter ended Dec 31, 2021 (from the annual report): revenue $11.1M, net income −$11.6M, EPS −$0.41
• Quarter ended Sep 30, 2021: revenue $14.7M, net income −$4.06M, EPS −$0.16

SABS cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$44.8M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$34.3M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$25.1M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$23.5M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow $1.99M, share buybacks n/a

SABS balance sheet

• Jun 30, 2026: cash $8.27M, total assets $238M, total liabilities $23.4M, shareholders' equity $215M
• Mar 31, 2026: cash $20.5M, total assets $248M, total liabilities $21.2M, shareholders' equity $227M
• Dec 31, 2025: cash $10.5M, total assets $173M, total liabilities $21.3M, shareholders' equity $151M
• Sep 30, 2025: cash $29.4M, total assets $183M, total liabilities $18.4M, shareholders' equity $165M
• Jun 30, 2025: cash $3.69M, total assets $30.1M, total liabilities $18.1M, shareholders' equity $12.0M
• Mar 31, 2025: cash $5.64M, total assets $38.1M, total liabilities $16.7M, shareholders' equity $21.4M
• Dec 31, 2024: cash $8.90M, total assets $44.2M, total liabilities $18.2M, shareholders' equity $26.0M
• Sep 30, 2024: cash $9.17M, total assets $53.8M, total liabilities $16.9M, shareholders' equity $36.9M

What is SABS's revenue?

SAB BIOTHERAPEUTICS INC reported $0 of revenue for the fiscal year ended December 2025.

Is SABS profitable?

No. SAB BIOTHERAPEUTICS INC lost $12.8M over the last four quarters.

What is SABS's EPS?

Diluted earnings per share over the last four quarters were $0.23; −$0.28 in the latest quarter.

SABS ownership and insider trades · All stocks